A Multi-center, Open-label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05% in Patients With Actinic Keratoses on Non-head Locations (Trunk and Extremities)

Inclusion Criteria:

- Patient is male or female and at least 18 years of age.

- Female patient must be of either:

- Non-childbearing potential, post-menopausal, or there is a confirmed clinical
history of sterility (e.g., the patient is without a uterus)

- Childbearing potential, provided there are negative urine pregnancy test results
prior to study treatment, to rule out pregnancy

Exclusion Criteria

- Cosmetic or therapeutic procedures within two weeks and within 2 cm of the selected
treatment area.

- Treatment with immunomodulators, interferon/ interferon inducers or systemic
medications that suppress the immune system within 4 weeks.

- Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy: within 8 weeks
and 2 cm of the selected treatment area.